BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Welchol (Colesevelam) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Welchol (Colesevelam)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06197763-328@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Welchol (Colesevelam): Phase 1/2 readout est. (NCT06197763)
DESCRIPTION:Welchol (Colesevelam)\, phase 1/2.\nStudy: Impact of Therapy Us
 ing Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circ
 ulation.\nEstimated primary completion: 30 July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/colesevelam#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06197763
URL:https://assetmemo.bio/drug/colesevelam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925997-328@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Welchol (Colesevelam): Phase 1 readout est. (NCT06925997)
DESCRIPTION:Welchol (Colesevelam)\, phase 1.\nStudy: Metabolic Effects of E
 ndogenous Bile Acids After Gastric Bypass Surgery\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /colesevelam#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06925997
URL:https://assetmemo.bio/drug/colesevelam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226440-328@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Welchol (Colesevelam): Phase 1/2 readout est. (NCT07226440)
DESCRIPTION:Welchol (Colesevelam)\, phase 1/2.\nStudy: Examining a Novel Ga
 strointestinal Intervention to Negate Environmental Toxicants (ENGINE)\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/colesevelam#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07226440
URL:https://assetmemo.bio/drug/colesevelam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07592858-328@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Welchol (Colesevelam): Phase 2 readout est. (NCT07592858)
DESCRIPTION:Welchol (Colesevelam)\, phase 2.\nStudy: Use of Bile Acid Bindi
 ng Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study\nEstim
 ated primary completion: 30 April 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/colesevelam#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07592858
URL:https://assetmemo.bio/drug/colesevelam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
